Hematologic Malignancies Clinical Trials

28 recruiting

Hematologic Malignancies Trials at a Glance

39 actively recruiting trials for hematologic malignancies are listed on ClinicalTrialsFinder across 6 cities in 53 countries. The largest study group is Phase 1 with 18 trials, with the heaviest enrollment activity in Houston, Duarte, and New York. Lead sponsors running hematologic malignancies studies include Beijing InnoCare Pharma Tech Co., Ltd., Incyte Corporation, and Merck Sharp & Dohme LLC.

Browse hematologic malignancies trials by phase

Treatments under study

About Hematologic Malignancies Clinical Trials

Looking for clinical trials for Hematologic Malignancies? There are currently 28 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematologic Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematologic Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting
Phase 1Phase 2

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1Phase 2

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Hematologic Malignancies
Sellas Life Sciences Group160 enrolled25 locationsNCT04588922
Recruiting
Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 2

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Hematologic Malignancies
M.D. Anderson Cancer Center35 enrolled1 locationNCT06807606
Recruiting
Phase 2

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.100 enrolled11 locationsNCT06665100
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 2

IVIG for Infection Prevention After CAR-T-Cell Therapy

Hematologic Malignancies
Fred Hutchinson Cancer Center150 enrolled7 locationsNCT05952804
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 1

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

Hematologic MalignanciesSolid Malignancies
Immunome, Inc.117 enrolled13 locationsNCT06823167
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Solid TumorsHematologic Malignancies
Incyte Corporation280 enrolled22 locationsNCT07195916
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Advanced Hematologic Malignancies
Sumitomo Pharma America, Inc.8 enrolled2 locationsNCT07444268
Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

Solid TumorsHematologic Malignancies
Mayo Clinic15,000 enrolled1 locationNCT02457962
Recruiting
Not Applicable

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Risk of Breast CancerRisk of Gynaecological CancerRisk of Colorectal Cancer+14 more
Gustave Roussy, Cancer Campus, Grand Paris5,909 enrolled1 locationNCT06907095
Recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Hematologic Malignancies
Asmaa Hassan mohamed Abdel Mawjoud38 enrolled2 locationsNCT04546945
Recruiting
Phase 1

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

Pediatric Hematologic Malignancies
Washington University School of Medicine50 enrolled1 locationNCT05011422
Recruiting
Phase 1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals42 enrolled11 locationsNCT03838926
Recruiting
Not Applicable

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

Hematologic Malignancies
University of Wisconsin, Madison38 enrolled1 locationNCT07285668